Manufacturer of Immune Regulation Proteins
Your Position : Home > Products > Interleukin and their receptor Cytokines > IL-35 (human):Fc (mouse) (rec.)
Product

IL-35 (human):Fc (mouse) (rec.)

Product Data

Synonyms : 

Interleukin-35

Properties

Host :

CHO cell

Sequence :

The human IL-35 complex composed of the Ebi3 subunit(NP_005746.2) (Arg21-Lys229) and the IL-12a(p35) subunit (NP_000873.2)(Arg57-Ser253) is fused through a polypeptide linker to the Fc portion of mouse IgG2a.

Molecular Mass:

75 KDa (monomer)

Purity :

>95%by SDS-PAGE under reducing conditions. 

Endotoxin Content :

<60 EU/mg as determined by LAL test. 

Activity:

Bioactivity was measured in a cell proliferation assay using 

anti-CD3 activated human peripheral mononuclear cells.

Shipping and Handling

Formulation :

Lyophilized from 0.2μm-filtered solution in PBS.

Reconstitution :

Reconstitute at 100μg/ml in sterile PBS.

Use / Stability :

 

Stable for at least 1 year after receipt when stored 

at -20°C. Working aliquots are stable for up to 3 months 

when stored at -20°C.

                        Avoid freeze/thaw cycles.

Documents
Description

Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a(p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.

Online Message